Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment

Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment

Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in the evolving landscape of multiple myeloma treatment. This significant study assesses the effectiveness of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) against the standard therapies, which include combinations of pomalidomide, bortezomib, and dexamethasone […]

VectivBio initiates phase 3 trial of apraglutide in patients with short bowel syndrome

VectivBio initiates phase 3 trial of apraglutide in patients with short bowel syndrome

VectivBio, a leading Swiss biotechnology firm, has announced the commencement of patient dosing in its phase 3 STARS clinical trial. This trial will evaluate the efficacy and safety of apraglutide, a synthetic glucagon-like peptide-2 (GLP-2) analog, in treating patients with Short Bowel Syndrome (SBS) with intestinal failure (SBS-IF). The STARS trial marks the largest phase […]

AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease

AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease

AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the first patient in its pivotal phase 3 clinical trial for AGB101, a promising treatment for amnestic Mild Cognitive Impairment (MCI) caused by Alzheimer’s Disease (AD). The trial, named HOPE4MCI, aims to assess the efficacy and safety of […]